Cassava falls after posting data from Alzheimer's study

NextTrip

09/09/2019 19:52

** Drug developer's shares  SAVA.O  fall ~9% to $1.3
    ** Co reports early data from a mid-stage trial testing its
lead drug PTI-125 in patients with Alzheimer's disease
 urn:newsml:reuters.com:*:nGNX27wTFX
    ** Maxim Group says several factors such as the trial's
small size of 13 patients could be weiging on the stock
    ** Peer Neurotrope Inc  NTRP.O  also presents data from a
mid-stage Alzheimer's trial showing that its experimental drug
failed to meet the trial's main goal  urn:newsml:reuters.com:*:nL3N2602WM
    ** SAVA may also be pressured by NTRP's failed study, Maxim
says 
    ** SAVA plans to start another larger mid-stage trial, which
is expected to begin in 3Q19, according to Maxim Group
    ** Up to Friday's close, SAVA had slumped 24% this year

 (Reporting by Manojna Maddipatla in Bengaluru)
 ((manojna.kalyani@thomsonreuters.com; within the U.S. +1 646
223 8780, outside the U.S. +91  80 6749 1692))